Chronic Spontaneous Urticaria

MILAN — Long term use of remibrutinib was safe and well tolerated for patients with chronic spontaneous urticaria, according to a poster presented at the European Academy of Dermatology and Venereology Congress.

Patients with chronic spontaneous urticaria experience more pleasure from scratching itches compared with patients with other skin conditions, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Remibrutinib reduced the need for rescue medication and improved symptoms among patients with chronic spontaneous urticaria, according to a study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress.

Patients with chronic spontaneous urticaria demonstrated improved outcomes related to idiopathic angioedema after taking omalizumab, according to a study presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

Patients with chronic spontaneous urticaria who used ligelizumab reported improvements in their sleep quality compared with patients who received omalizumab or placebo, according to a study published in Clinical and Translational Allergy.

BOSTON — Chronic spontaneous urticaria has a negative impact on patients’ lives, including on both mental and physical health and daily activities, according to a poster presented at the American Academy of Dermatology Annual Meeting.

PHOENIX — Patients with H1 antihistamine-resistant chronic spontaneous urticaria experienced improvements with dupilumab, according to a study presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

Remibrutinib provided significant improvement in chronic spontaneous urticaria in a phase 2b dose affirming trial presented at the EADV virtual congress.

Ligelizumab and omalizumab were found to be the most effective treatments for adolescent and adult patients with chronic spontaneous urticaria who had failed to respond to H1 antihistamines, according to a study.

Dupixent reduced both itch and hives in patients with moderate to severe chronic spontaneous urticaria in a pivotal phase 3 trial, Regeneron and Sanofi announced in a press release.